LitAlert ~~ GeneLit.com

    • Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland.
    • Zlowocka-Perlowska E, Toloczko-Grabarek A, Narod SA, Lubinski J.
    • Hered Cancer Clin Pract. 2022 Apr 8;20(1):13. doi: 10.1186/s13053-022-00220-6.
    • Contribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testing.
    • Li N, Zethoven M, McInerny S, Healey E, DeSilva D, Devereux L, Scott RJ, James PA, Campbell IG.
    • J Med Genet. 2022 Apr 8:jmedgenet-2021-108399. doi: 10.1136/jmedgenet-2021-108399. Epub ahead of print.
    • PARP inhibition in breast cancer: progress made and future hopes.
    • Tung N, Garber JE.
    • NPJ Breast Cancer. 2022 Apr 8;8(1):47. doi: 10.1038/s41523-022-00411-3.
    • Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis.
    • Pomerantz A, Tsoref D, Grubstein A, Wadhawker S, Rapson Y, Gadiel I, Goldvaser H, Feldhamer I, Hammerman A, Shochat T, Sharon E, Kedar I, Yerushalmi R.
    • Breast Cancer Res Treat. 2022 Apr 7. doi: 10.1007/s10549-021-06498-9. Epub ahead of print.
    • Germline BRCA variants, lifestyle and ovarian cancer survival.
    • Gersekowski K, Delahunty R, Alsop K, Goode EL, Cunningham JM, Winham SJ, Pharoah P, Song H, Jordan S, Fereday S, DeFazio A, Friedlander M, Obermair A, the OPAL Study Group, the AOCS Group, Webb PM.>
    • Gynecol Oncol. 2022 Apr 7:S0090-8258(22)00202-5. doi: 10.1016/j.ygyno.2022.03.020. Epub ahead of print.